Inspire Medical Systems(NYSE) INSP

Inspire helps people with sleep apnea breathe during the night. It makes a small device that stays inside the body. This helps patients who cannot use standard masks and air pumps.

Inside the System

• Inspire System: An implanted device that monitors breathing and stimulates a nerve to keep the tongue from blocking the airway.
• Inspire V: A next-generation neurostimulator that includes a built-in sensor to detect breathing without needing an extra wire in the chest.
• SleepSync Platform: A cloud-based tool that allows doctors and patients to monitor therapy results and usage from a distance.
• Patient Remote: A handheld controller used by patients to turn the therapy on before sleep and off upon waking.

Strategic Steps Forward

• Launched the Inspire V neurostimulator in 2024 after receiving approval from the FDA (U.S. Food and Drug Administration).
• Expanded treatment indications in 2023 to include patients with higher weights and more severe breathing blockages.
• Received FDA authorization in 2023 to provide the therapy to children with Down syndrome who suffer from sleep apnea.
• Optimized the U.S. sales team in 2025 by increasing the number of clinical experts to support doctors during implants.

Why the Technology Wins

The company uses a closed-loop system that adjusts stimulation based on a patient's natural breathing cycle rather than a fixed timer. It maintains a direct sales force in major markets like the U.S. and Japan while using distribution partners across other parts of Asia.

By the Numbers

• Revenue reached $269.1 million in Q4 2025, up 12.2% from Q4 2024.
• Operating income reached $46.1 million in Q4 2025, up 44.6% year-over-year.
• Net income reached $136.1 million in Q4 2025, up 286.4% from the previous year.
• Free cash flow hit $41.8 million in Q4 2025, down 32.7% year-over-year.
• Market capitalization reached $2.7 billion in Q4 2025, down 51.7% from $5.5 billion in Q4 2024.

Bottom Line

Inspire has evolved from a medical device startup into a global technology company with a comprehensive digital health platform. Its focus on clinical evidence and less invasive surgery has helped it treat more than 125,000 patients who struggle with traditional masks.